Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 2Terminated 2Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 12Purpura 1Paraproteinemias 1Neoplasms 1Nausea 1Natural Killer/T-cell Lymphoma 1Macroglossia 1Lymphoproliferative Disorders 1Lymphadenopathy 1Immunoproliferative Disorders 1Immunoglobulin Light-chain Amyloidosis 1Hepatomegaly 1Hematologic Neoplasms 1Gastrointestinal Hemorrhage 1Diarrhea 1Constipation 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × isatuximab × Clear all
NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Completed
514 enrolled
LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡